Georgia's Online Cancer Information Center

Find A Clinical Trial

Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 4 - LGX818 for Patients With BRAFV600 Mutated Tumors

Status
Active
Cancer Type
Hematologic Malignancies
Trial Phase
Phase II
Eligibility
18 and older, Male and Female
Study Type
Treatment
NCD ID
NCT01981187
Protocol IDs
CLGX818AUS03 (primary)
Study Sponsor
Novartis Pharmaceuticals
NCI Full Details

Summary

The purpose of this signal seeking study is to determine whether treatment with LGX818 demonstrates sufficient efficacy in select pathway-activated solid tumors and/or hematologic malignancies to warrant further study

Treatment Sites in Georgia

University Cancer and Blood Center, LLC - Athens Medical Oncology


3320 Old Jefferson Road
Building 700
Athens, GA 30607
706-353-2990 x279
www.universitycancer.com

Georgia CORE

 

Hearts and Minds Dedicated to Improving Cancer Care

Georgia CORE is a public-private partnership that creates collaboration among the state’s cancer organizations and institutions to connect more Georgians to quality, personalized cancer care. We welcome you to this one-of-a-kind online information center for all things related to cancer and survivorship care in Georgia.